Spyre Therapeutics Inc (SYRE) FY Conference June 09, 2025 09:20 AM ET Speaker0 Thank you for joining us. I'm Paul Choi, and I cover biotechnology here at the firm. It's our pleasure to welcome Spire, and we have Cameron here on on stage with us. Maybe to to kick it off, Cameron, can just give us a brief overview of Spire and just sort of the key programs and technologies under pending pending the company? Yeah. Speaker1 Of course. And so and thanks for having us. It's a great event as always. So the backgro ...

On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027Reported extended follow-up Phase 1 data for SPY001, supporting that the molecule is well tolerated, has a pharmacokinetic ("PK") profile enabling quarterly or biannual dosing, and provides complete target engagement at expected Phase 2 trough concentrationsRemain on track to report interim Phase 1 data for SPY002 later this quart ...

Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Bio ...